Imperial College London

ProfessorLucaMagnani

Faculty of MedicineDepartment of Surgery & Cancer

Chair in Cancer Adaptation and Evolution
 
 
 
//

Contact

 

+44 (0)20 7594 2808l.magnani CV

 
 
//

Location

 

137ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Borgoni:2020:10.1101/2020.06.08.139659,
author = {Borgoni, S and Sofyal, E and Soleimani, M and Wilhelm, H and Müller-Decker, K and Will, R and Noronha, A and Verschure, PJ and Yarden, Y and Magnani, L and van, Kampen AHC and Moerland, PD and Wiemann, S},
doi = {10.1101/2020.06.08.139659},
title = {Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer},
url = {http://dx.doi.org/10.1101/2020.06.08.139659},
year = {2020}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - <jats:title>Abstract</jats:title><jats:p>Breast cancer is one of the leading causes of death for women worldwide. Patients whose tumors express Estrogen Receptor α (ERα) account for around 70% of cases and are mostly treated with targeted endocrine therapy. However, 40% of these tumors eventually relapse due to resistance development and further treatment of these patients is highly ineffective. In this study we profiled the early phases of the resistance development process to uncover drivers of this phenomenon. Time-resolved analysis revealed that ATF3, a member of the ATF/CREB family of transcription factors, acts as a novel regulator of the response to therapy via rewiring of central signaling processes towards the adaptation to endocrine treatment. ATF3 was found to be essential in controlling crucial processes such as proliferation, cell cycle and apoptosis during the early response to treatment through the regulation of MAPK/AKT signaling pathways. Its essential role was confirmed <jats:italic>in vivo</jats:italic> in a mouse model and elevated expression of ATF3 was verified in patient datasets, adding clinical relevance to our findings. This study proposes ATF3 as a novel mediator of endocrine resistance development in breast cancer and elucidates its role in the regulation of downstream pathways activities.</jats:p>
AU - Borgoni,S
AU - Sofyal,E
AU - Soleimani,M
AU - Wilhelm,H
AU - Müller-Decker,K
AU - Will,R
AU - Noronha,A
AU - Verschure,PJ
AU - Yarden,Y
AU - Magnani,L
AU - van,Kampen AHC
AU - Moerland,PD
AU - Wiemann,S
DO - 10.1101/2020.06.08.139659
PY - 2020///
TI - Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer
UR - http://dx.doi.org/10.1101/2020.06.08.139659
ER -